Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key functions of full-length dystrophin and allows it be delivered more effectively ...

Solid claims the results, while early, suggest SGT-003 could be more potent than Sarepta Therapeutics’ Elevidys, the only approved Duchenne gene therapy. The company intends to discuss an ...

We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at where Sarepta Therapeutics, Inc.

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

The cuts hit the FDA’s medical device center particularly hard, impacting product reviewers and researchers of AI-enabled ...

Eli Lilly has been a terrific stock to own for the past five years, thanks to its excellent clinical and regulatory progress.

The company also said its medication delivered genetic material to muscles at a level five times higher than ELEVIDYS with a dose 25% lower. These data indicate that the treatment could be safer ...

It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%.” - The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, January ...

Roche announced positive topline results from year two of the EMBARK trial, a global, randomised, double-blind phase III study of Elevidys (delandistrogene moxeparvovec), the first approved gene ...